Connection

JULIE GASTIER-FOSTER to Risk Factors

This is a "connection" page, showing publications JULIE GASTIER-FOSTER has written about Risk Factors.
Connection Strength

0.182
  1. Genomic landscape of Down syndrome-associated acute lymphoblastic leukemia. Blood. 2023 07 13; 142(2):172-184.
    View in: PubMed
    Score: 0.020
  2. Revised Neuroblastoma Risk Classification System: A Report From the Children's Oncology Group. J Clin Oncol. 2021 10 10; 39(29):3229-3241.
    View in: PubMed
    Score: 0.017
  3. Maintaining Outstanding Outcomes Using Response- and Biology-Based Therapy for Intermediate-Risk Neuroblastoma: A Report From the Children's Oncology Group Study ANBL0531. J Clin Oncol. 2019 12 01; 37(34):3243-3255.
    View in: PubMed
    Score: 0.015
  4. No evidence that G6PD deficiency affects the efficacy or safety of daunorubicin in acute lymphoblastic leukemia induction therapy. Pediatr Blood Cancer. 2019 06; 66(6):e27681.
    View in: PubMed
    Score: 0.015
  5. Treatment of Stage IV Favorable Histology Wilms Tumor With Lung Metastases: A Report From the Children's Oncology Group AREN0533 Study. J Clin Oncol. 2018 06 01; 36(16):1564-1570.
    View in: PubMed
    Score: 0.014
  6. Impact of Initial CSF Findings on Outcome Among Patients With National Cancer Institute Standard- and High-Risk B-Cell Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group. J Clin Oncol. 2017 Aug 01; 35(22):2527-2534.
    View in: PubMed
    Score: 0.013
  7. Histology, fusion status, and outcome in metastatic rhabdomyosarcoma: A report from the Children's Oncology Group. Pediatr Blood Cancer. 2017 Dec; 64(12).
    View in: PubMed
    Score: 0.013
  8. Germline genetic variation in ETV6 and risk of childhood acute lymphoblastic leukaemia: a systematic genetic study. Lancet Oncol. 2015 Dec; 16(16):1659-66.
    View in: PubMed
    Score: 0.012
  9. Clinical Application of Prognostic Gene Expression Signature in Fusion Gene-Negative Rhabdomyosarcoma: A Report from the Children's Oncology Group. Clin Cancer Res. 2015 Oct 15; 21(20):4733-9.
    View in: PubMed
    Score: 0.011
  10. Prognostic significance of minimal residual disease in high risk B-ALL: a report from Children's Oncology Group study AALL0232. Blood. 2015 Aug 20; 126(8):964-71.
    View in: PubMed
    Score: 0.011
  11. IgH-V(D)J NGS-MRD measurement pre- and early post-allotransplant defines very low- and very high-risk ALL patients. Blood. 2015 May 28; 125(22):3501-8.
    View in: PubMed
    Score: 0.011
  12. A genome-wide association study of susceptibility to acute lymphoblastic leukemia in adolescents and young adults. Blood. 2015 Jan 22; 125(4):680-6.
    View in: PubMed
    Score: 0.011
  13. Age-dependent prognostic effect by Mitosis-Karyorrhexis Index in neuroblastoma: a report from the Children's Oncology Group. Pediatr Dev Pathol. 2014 Nov-Dec; 17(6):441-9.
    View in: PubMed
    Score: 0.011
  14. PAX-FOXO1 fusion status drives unfavorable outcome for children with rhabdomyosarcoma: a children's oncology group report. Pediatr Blood Cancer. 2013 Sep; 60(9):1411-7.
    View in: PubMed
    Score: 0.010
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.